Alterations to endothelial membrane composition and structure as a driver of the endotheliopathy of trauma
Project Number1R01GM151631-01A1
Former Number1R01GM151631-01
Contact PI/Project LeaderJACKSON-WEAVER, OLAN
Awardee OrganizationTULANE UNIVERSITY OF LOUISIANA
Description
Abstract Text
Project Abstract
Severe hemorrhage is a life-threatening condition that often occurs in trauma. Hemorrhagic shock and the
hypotension and tissue ischemia that results is associated with endothelial damage and dysfunction that is
thought to contribute to associated complications and death. Recently, it has been appreciated that a
proteoglycan structure that lines blood vessels, known as the endothelial glycocalyx, is damaged during
trauma and hemorrhage. This glycocalyx damage is thought to contribute to generalized blood vessel
disfunction, multi-organ failure, and coagulopathy, together termed the Endotheliopathy of Trauma. Trauma
patients with high plasma glycocalyx components die at higher rates, both due to uncontrolled hemorrhage, as
well as an increase in multi-organ failure. Despite the potential importance of this mechanism, signaling events
leading to acute endothelial glycocalyx shedding are largely undefined. We have previously found that
metabolism of the citric acid cycle intermediate succinate drives the acute shedding of the glycocalyx. We also
observed an increase in membrane lysophospholipids in a cell culture model of hypoxia-reoxygenation, as well
as increases in the interaction between matrix metalloproteinases (MMPs) and the glycocalyx constituent
syndecan-1. These findings led us to hypothesize that the increased succinate metabolism during hemorrhage-
resuscitation causes reactive oxygen species production and lipid oxidation, which leads to phospholipase A2-
mediated generation of lysophospholipids and plasma membrane reorganization, allowing MMPs to degrade
the glycocalyx. We propose that a specialized protein-lipid domain forms in the plasma membrane consisting
of lysophospholipids, MMPs, and glycocalyx proteins, which we term a “sheddosome” domain. In two specific
aims, we will 1.) Determine how membrane reorganization mediates glycocalyx shedding through the formation
of “sheddosome” domains in a general hypoxia-reoxygenation model. 2.) Determine how lysophospholipid-
mediated membrane reorganization leads to the endotheliopathy of trauma. This work will define a mechanism
by which alterations in succinate metabolism drive changes in membrane structure, leading to glycocalyx
damage, coagulopathy, and organ failure. This new knowledge of the acute vascular events in traumatic
hemorrhage will inform future therapies to increase survival in these patients.
Public Health Relevance Statement
Project Narrative
Trauma is the most prevalent cause of death for those under 40 years of age in the United States. The blood
loss that often occurs in trauma causes damage to the lining of the blood vessels. This damage causes
disordered blood clotting, as well as multi-organ failure, which leads to high death rates in trauma patients. The
proposed project is relevant to public health through investigation of the mechanism underlying this vascular
damage, and may identify new therapeutic strategies to reduce the high rates of death in trauma patients with
severe blood loss.
No Sub Projects information available for 1R01GM151631-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01GM151631-01A1
Patents
No Patents information available for 1R01GM151631-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01GM151631-01A1
Clinical Studies
No Clinical Studies information available for 1R01GM151631-01A1
News and More
Related News Releases
No news release information available for 1R01GM151631-01A1
History
No Historical information available for 1R01GM151631-01A1
Similar Projects
No Similar Projects information available for 1R01GM151631-01A1